Rakuten Medical

[Not Yet Scheduled]
Rakuten Medical, Inc. (RMI) is a privately funded, clinical-stage biotechnology company with offices in the U.S., Japan, Taiwan, Germany and the Netherlands. Rakuten Medical aims to become a leader in precision-targeted medicines through Rakuten Medical’s Illuminox™, its proprietary, anti-cancer treatment platform. The Company’s lead product, ASP-1929, the first investigational product based on RMI’s Illuminox, has achieved Fast Track designation from both the FDA and the Japanese Ministry of Health, Labour, and Welfare. ASP-1929 is currently the subject of a global, Phase 3 clinical trial for recurrent head and neck squamous cell carcinoma. Additional Phase 2 studies for ASP-1929 are also underway to evaluate the safety in patients with other cancer types.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
ASP-1929
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chairman and CEO
Rakuten Medical